EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disrupted minor intron splicing activates reductive carboxylation-mediated lipogenesis to drive metabolic dysfunction–associated steatotic liver disease progression

Yinkun Fu, Xin Peng, Hongyong Song, Xiaoyun Li, Yang Zhi, Jieting Tang, Yifan Liu, Ding Chen, Wenyan Li, Jing Zhang, Jing Ma, Ming He und 2 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci186478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Yinkun Fu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Di…. Hauptthemen laut MEDLINE: Lipogenesis, Introns, RNA Splicing, Fatty Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Clinical Research Innovation and Development Fund of Renji Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant RNA splicing is tightly linked to diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD). In this study, we revealed that minor intron splicing, a unique and conserved RNA processing event, is largely disrupted upon the progression of metabolic dysfunction–associated steatohepatitis (MASH) in mice and humans. We demonstrated that deficiency of minor intron splicing in the liver induced MASH transition upon obesity-induced insulin resistance and LXR activation. Mechanistically, inactivation of minor intron splicing led to minor intron retention of Insig1 and Insig2 , resulting in premature termination of translation, which drove proteolytic activation of SREBP1c. This mechanism was conserved in patients with MASH. Notably, disrupted minor intron splicing activated glutamine reductive metabolism for de novo lipogenesis through induction of Idh1, which caused accumulation of ammonia in the liver, thereby initiating hepatic fibrosis upon LXR activation. Ammonia clearance or IDH1 inhibition blocked hepatic fibrogenesis and mitigated MASH progression. More importantly, overexpression of Zrsr1 restored minor intron retention and ameliorated the development of MASH, indicating that dysfunctional minor intron splicing is an emerging pathogenic mechanism that drives MASH progression. Additionally, our results suggest that reductive carboxylation flux triggered by minor intron retention in hepatocytes serves as a crucial checkpoint and potential target for MASH therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipogenesisIntronsRNA SplicingFatty LiverAnimalsHumansMiceMaleDisease ProgressionLiver

Stichwörter der Autor:innen

Amino acid metabolismFibrosisHepatologyMetabolismRNA processing

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education and.
  • Institute for Translational Medicine on Cell Fate and Disease, Shanghai Ninth People's Hospital, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Sha…
  • Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine; NHC Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Shanghai, China.
  • Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Pathology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Clinical Research Innovation and Development Fund of Renji Hospital
  • National key R&D program of China
  • Major Project of National Thirteenth Five Plan
  • Innovative research team of high-level local universities in Shanghai

Zitieren

APA

Fu, Y., Peng, X., Song, H., Li, X., Zhi, Y., Tang, J., Liu, Y., Chen, D., Li, W., Zhang, J., Ma, J., He, M., Mao, Y., & Zhao, X. Y. (2025). Disrupted minor intron splicing activates reductive carboxylation-mediated lipogenesis to drive metabolic dysfunction–associated steatotic liver disease progression. Journal of Clinical Investigation. https://doi.org/10.1172/jci186478

Vancouver

Fu Y, Peng X, Song H, Li X, Zhi Y, Tang J, et al. Disrupted minor intron splicing activates reductive carboxylation-mediated lipogenesis to drive metabolic dysfunction–associated steatotic liver disease progression. Journal of Clinical Investigation. 2025. doi:10.1172/jci186478

BibTeX
@article{Fu2025,
  author = {Fu, Yinkun and Peng, Xin and Song, Hongyong and Li, Xiaoyun and Zhi, Yang and Tang, Jieting and Liu, Yifan and Chen, Ding and Li, Wenyan and Zhang, Jing and Ma, Jing and He, Ming and Mao, Yimin and Zhao, Xu-Yun},
  title = {Disrupted minor intron splicing activates reductive carboxylation-mediated lipogenesis to drive metabolic dysfunction–associated steatotic liver disease progression},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci186478}
}
Kostenlos starten →